| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |